Allison Betof Warner, MD from Stanford Healthcare discusses recent advancements in treating advanced melanoma with a newly FDA-approved cell-based therapy. This innovative treatment is designed for patients who…
A groundbreaking trial in the UK is testing the world’s first “personalized” mRNA vaccine against the deadliest form of skin cancer, melanoma. This innovative vaccine is tailored to…
Rajdeep Mysore, MD discusses melanoma, the most dangerous type of skin cancer. Originating from melanocytes, the color-producing cells in the skin, melanomas often appear as black or brown…
After prior case studies showed promising results with PD-1 inhibition followed by chemotherapy, a group of doctors, led by Georgia Sofia Karachaliou, MD, MSc, of the Department of Medicine…
Published final results of the DeCOG-SLT trial add evidence that patients who have a positive sentinel lymph-node biopsy, and have immediate complete lymph node dissection, do not achieve…
There have been many changes in the treatment landscape of stage II and stage III melanoma over the past decade. This article takes a look at the benefits…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA,…
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives…
Early data from the phase III CheckMate 067 trial, reported in September 2017, showed that patients with advanced melanoma treated with nivolumab, with or without ipilimumab, maintained their quality…
A retrospective study’s multivariate analysis suggests that in the treatment of early invasive melanoma, the use of Mohs micrographic surgery is associated with better outcomes when compared with…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
With the growth of immunotherapies in recent years as an effective melanoma treatment option, there are still patients who do not respond well to immunotherapies. Hildur Helgadottir, MD,…
